Vincent Pascat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vincent Pascat has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Inga Prokopenko
Department of Clinical & Experimental Medicine, University of Surrey, Guildford GU2 7XH, UK
4 shared publications - Amélie Bonnefond
Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France
3 shared publications - Marika Kaakinen
University of Surrey
3 shared publications - Philippe Froguel
Inserm U1283, CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France
3 shared publications - Yevheniya Sharhorodska
Section of Statistical Multi-Omics, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK
3 shared publications - Zhanna Balkhiyarova
Department of Endocrinology, Faculty of General Medicine, Bashkir State Medical University, 450008 Ufa, Russia
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 4811
Epigenetic landscapes in human pancreatic islets reveal distinct drivers for adaptation to age and type 2 diabetes
Age is the strongest risk factor for type 2 diabetes, yet their independent contribution to pancreatic islet dysfunction remains unclear. We integrate DNA methylation, transcriptomic, and genotyping data from 144 islet donors. We identify 996 age- and 902 T2D-associated CpGs with minimal overlap, and 251 age- and 310 diabetes CpG target genes, usually distant from the CpG. Age-linked CpGs are enriched in promoters, form co-regulated gene modules, link to beta-cell function, including insulin secretion. Diabetes-associated CpGs are enriched in enhancer/non-regulatory regions, and modules suggest stress-induced epigenetic drift. CpG-gene associations are independent of genetic variation. Mendelian randomisation supports a causal role for age-associated CpGs regulating KLHL42, a T2D GWAS locus. A blood-based methylation risk score based on age-linked CpGs correlates with insulin secretion and improves diabetes classification when combined with genetic risk (AUC = 0.91). Altogether, age is associated with a coordinated epigenetic programme, whereas diabetes links to a heterogeneous, stress-related epigenetic signature.
- 3 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 4811
Open AccessEpigenetic landscapes in human pancreatic islets reveal distinct drivers for adaptation to age and type 2 diabetes
Age is the strongest risk factor for type 2 diabetes, yet their independent contribution to pancreatic islet dysfunction remains unclear. We integrate DNA methylation, transcriptomic, and genotyping data from 144 islet donors. We identify 996 age- and 902 T2D-associated CpGs with minimal overlap, and 251 age- and 310 diabetes CpG target genes, usually distant from the CpG. Age-linked CpGs are enriched in promoters, form co-regulated gene modules, link to beta-cell function, including insulin secretion. Diabetes-associated CpGs are enriched in enhancer/non-regulatory regions, and modules suggest stress-induced epigenetic drift. CpG-gene associations are independent of genetic variation. Mendelian randomisation supports a causal role for age-associated CpGs regulating KLHL42, a T2D GWAS locus. A blood-based methylation risk score based on age-linked CpGs correlates with insulin secretion and improves diabetes classification when combined with genetic risk (AUC = 0.91). Altogether, age is associated with a coordinated epigenetic programme, whereas diabetes links to a heterogeneous, stress-related epigenetic signature.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Large-scale genomic investigation into factors contributing to metabolic derangements and their comorbidity
Etude génomique à grande échelle des facteurs conduisant à des dérangements métaboliques et leur comorbidité: Les comorbidités, co-occurrences de plusieurs maladies chez un seul individu, représentent un défi pour les systèmes de santé : les patients avec plusieurs maladies atteignent difficilement leurs objectifs de traitement et sont à risques d’autres complications. La médecine de précision, qui exploite l’ensemble des données disponibles pour adapter le traitement aux profils individuels des patients, constitue une approche prometteuse pour relever ce défi. Une des informations qu’il est possible d’extraire pour appliquer la médecine de précision est la donnée génétique. En effet, les mutations génétiques germinales ont le même effet tout au long de la vie d’un individu, fournissant ainsi une base cohérente pour comprendre le développement de la maladie, sa progression, et la réponse au traitement. Les avancées récentes en génétique et en statistique ont permis le développement d’études multiomiques à grande échelle. Ces données ont permis aux chercheurs de mener des investigations génomiques approfondies, révélant des informations précieuses sur l’architecture génétique de maladies complexes telles que le diabète de type 2 et l’hypertension. Dans cette thèse, j’ai exploité des ensembles de données multiomiques à grande échelle pour aborder plusieurs questions non résolues liées aux comorbidités métaboliques. Mes recherches se sont concentrées sur trois projets principaux. Le premier fut le développement d’un package R, comorbidPGS, conçu pour évaluer la prédiction réciproque du risque génétique entre phénotypes à l’aide de scores polygéniques, un outil précieux en génétique statistique permettant d’estimer la prédisposition génétique d’une condition. Cet outil facilite l’exploration de la prédisposition génétique aux maladies comorbides. Le deuxième projet utilise comorbidPGS pour explorer l’architecture génétique sous-jacente à la comorbidité entre le diabète et l’hypertension artérielle. Bien que les génétiques du diabète et de l’hypertension aient été largement étudiées séparément, leur base génétique commune est encore mal comprise. En regroupant les variants génétiques associés au diabète de type 2 et/ou à l’hypertension artérielle, j’ai exploré les mécanismes sous-jacents qui contribuent à leur comorbidité. Le troisième projet de recherche se concentre sur l’effet des niveaux élevés de lipoprotéine(a) sur l’hypercholestérolémie familiale, une maladie héréditaire caractérisée par des niveaux élevés de cholestérol des lipoprotéines de basse densité. La lipoprotéine(a) et l’hypercholestérolémie sont tous deux associés à des comorbidités cardiovasculaires. Les patients atteints d’hypercholestérolémie familiale présentent souvent des niveaux de lipoprotéine(a) élevés. De plus, le cholestérol associé à la lipoprotéine(a) peut être mal classé en cholestérol des lipoprotéines de basse densité, entraînant des erreurs dans le diagnostic de l’hypercholestérolémie familiale. En utilisant le plus grand ensemble de données de séquençage d’exome complet de la UK Biobank, j’ai examiné l’influence des niveaux de lipoprotéine(a) sur le diagnostic de l’hypercholestérolémie familiale, et évalué les contributions polygéniques et monogéniques sur l’hypercholestérolémie générale. Ce travail a permis de souligner l’importance d’intégrer plusieurs couches de preuves omiques pour démêler les interactions complexes entre les mécanismes biologiques corrélés, associés et/ou causaux. Il met également en évidence la valeur des scores polygéniques dans la prédiction des risques de complications au cours de la vie, même pour des maladies liées au vieillissement telles que le diabète ou l’hypertension. Faisant progresser la compréhension des relations génétiques entre les maladies complexes, cette thèse permet d’imaginer des diagnostics plus précis, des interventions thérapeutiques ciblées, contribuant ainsi à se rapprocher du paradigme de la médecine de précision.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Large-scale genomic investigation into factors contributing to metabolic derangements and their comorbidity
Etude génomique à grande échelle des facteurs conduisant à des dérangements métaboliques et leur comorbidité: Les comorbidités, co-occurrences de plusieurs maladies chez un seul individu, représentent un défi pour les systèmes de santé : les patients avec plusieurs maladies atteignent difficilement leurs objectifs de traitement et sont à risques d’autres complications. La médecine de précision, qui exploite l’ensemble des données disponibles pour adapter le traitement aux profils individuels des patients, constitue une approche prometteuse pour relever ce défi. Une des informations qu’il est possible d’extraire pour appliquer la médecine de précision est la donnée génétique. En effet, les mutations génétiques germinales ont le même effet tout au long de la vie d’un individu, fournissant ainsi une base cohérente pour comprendre le développement de la maladie, sa progression, et la réponse au traitement. Les avancées récentes en génétique et en statistique ont permis le développement d’études multiomiques à grande échelle. Ces données ont permis aux chercheurs de mener des investigations génomiques approfondies, révélant des informations précieuses sur l’architecture génétique de maladies complexes telles que le diabète de type 2 et l’hypertension. Dans cette thèse, j’ai exploité des ensembles de données multiomiques à grande échelle pour aborder plusieurs questions non résolues liées aux comorbidités métaboliques. Mes recherches se sont concentrées sur trois projets principaux. Le premier fut le développement d’un package R, comorbidPGS, conçu pour évaluer la prédiction réciproque du risque génétique entre phénotypes à l’aide de scores polygéniques, un outil précieux en génétique statistique permettant d’estimer la prédisposition génétique d’une condition. Cet outil facilite l’exploration de la prédisposition génétique aux maladies comorbides. Le deuxième projet utilise comorbidPGS pour explorer l’architecture génétique sous-jacente à la comorbidité entre le diabète et l’hypertension artérielle. Bien que les génétiques du diabète et de l’hypertension aient été largement étudiées séparément, leur base génétique commune est encore mal comprise. En regroupant les variants génétiques associés au diabète de type 2 et/ou à l’hypertension artérielle, j’ai exploré les mécanismes sous-jacents qui contribuent à leur comorbidité. Le troisième projet de recherche se concentre sur l’effet des niveaux élevés de lipoprotéine(a) sur l’hypercholestérolémie familiale, une maladie héréditaire caractérisée par des niveaux élevés de cholestérol des lipoprotéines de basse densité. La lipoprotéine(a) et l’hypercholestérolémie sont tous deux associés à des comorbidités cardiovasculaires. Les patients atteints d’hypercholestérolémie familiale présentent souvent des niveaux de lipoprotéine(a) élevés. De plus, le cholestérol associé à la lipoprotéine(a) peut être mal classé en cholestérol des lipoprotéines de basse densité, entraînant des erreurs dans le diagnostic de l’hypercholestérolémie familiale. En utilisant le plus grand ensemble de données de séquençage d’exome complet de la UK Biobank, j’ai examiné l’influence des niveaux de lipoprotéine(a) sur le diagnostic de l’hypercholestérolémie familiale, et évalué les contributions polygéniques et monogéniques sur l’hypercholestérolémie générale. Ce travail a permis de souligner l’importance d’intégrer plusieurs couches de preuves omiques pour démêler les interactions complexes entre les mécanismes biologiques corrélés, associés et/ou causaux. Il met également en évidence la valeur des scores polygéniques dans la prédiction des risques de complications au cours de la vie, même pour des maladies liées au vieillissement telles que le diabète ou l’hypertension. Faisant progresser la compréhension des relations génétiques entre les maladies complexes, cette thèse permet d’imaginer des diagnostics plus précis, des interventions thérapeutiques ciblées, contribuant ainsi à se rapprocher du paradigme de la médecine de précision.
- Open Access
- 9 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 1446
Partitioned polygenic scores show mechanistic heterogeneity in type 2 diabetes and hypertension comorbidity
Type 2 diabetes and hypertension are common health conditions that often occur together, suggesting shared biological mechanisms. To explore this relationship, we analyse large-scale multiomic data to uncover genetic factors underlying type 2 diabetes and blood pressure comorbidity. We curate 1304 independent single-nucleotide variants associated with type 2 diabetes and blood pressure, grouping them into five clusters related to metabolic syndrome, inverse type 2 diabetes/blood pressure risk, impaired pancreatic beta-cell function, higher adiposity, and vascular dysfunction. Colocalization with tissue-specific gene expression highlights significant enrichment in pathways related to thyroid function and fetal development. Partitioned polygenic scores derived from these clusters improve risk prediction for type 2 diabetes/hypertension comorbidity, identifying individuals with more than twice the usual susceptibility. These results reveal a mechanistically heterogeneous genetic architecture shared between type 2 diabetes and blood pressure, enhancing comorbidity risk prediction. Partitioned polygenic risk scores offer a promising approach for early risk stratification, personalised prevention, and improved management of these interconnected conditions.
- 9 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 1446
Open AccessPartitioned polygenic scores show mechanistic heterogeneity in type 2 diabetes and hypertension comorbidity
Type 2 diabetes and hypertension are common health conditions that often occur together, suggesting shared biological mechanisms. To explore this relationship, we analyse large-scale multiomic data to uncover genetic factors underlying type 2 diabetes and blood pressure comorbidity. We curate 1304 independent single-nucleotide variants associated with type 2 diabetes and blood pressure, grouping them into five clusters related to metabolic syndrome, inverse type 2 diabetes/blood pressure risk, impaired pancreatic beta-cell function, higher adiposity, and vascular dysfunction. Colocalization with tissue-specific gene expression highlights significant enrichment in pathways related to thyroid function and fetal development. Partitioned polygenic scores derived from these clusters improve risk prediction for type 2 diabetes/hypertension comorbidity, identifying individuals with more than twice the usual susceptibility. These results reveal a mechanistically heterogeneous genetic architecture shared between type 2 diabetes and blood pressure, enhancing comorbidity risk prediction. Partitioned polygenic risk scores offer a promising approach for early risk stratification, personalised prevention, and improved management of these interconnected conditions.
- Open Access
Mechanistic Heterogeneity in Type 2 Diabetes and Hypertension Comorbidity Revealed with Partitioned Polygenic Scores
Summary: Type 2 diabetes (T2D) and hypertension are common health conditions that often occur together, suggesting shared biological mechanisms. To explore this relationship, we analysed large-scale multiomic data to uncover genetic factors underlying T2D and blood pressure (BP) comorbidity. We curated 1,304 independent single-nucleotide variants (SNVs) associated with T2D/BP, grouping them into five clusters related to metabolic syndrome, inverse T2D-BP risk, impaired pancreatic beta-cell function, higher adiposity, and vascular dysfunction . Colocalisation with tissue-specific gene expression highlighted significant enrichment in pathways related to thyroid function and fetal development. Partitioned polygenic scores (PGS) derived from these clusters improved risk prediction for T2D-hypertension comorbidity, identifying individuals with more than twice usual susceptibility. These results reveal complex genetic basis of shared T2D and BP mechanistic heterogeneity, enhancing comorbidity risk prediction. Partitioned PGSs offer promising approach for early risk stratification, personalised prevention, and improved management of these interconnected conditions, supporting precision medicine and public health initiatives.
Open AccessMechanistic Heterogeneity in Type 2 Diabetes and Hypertension Comorbidity Revealed with Partitioned Polygenic Scores
Summary: Type 2 diabetes (T2D) and hypertension are common health conditions that often occur together, suggesting shared biological mechanisms. To explore this relationship, we analysed large-scale multiomic data to uncover genetic factors underlying T2D and blood pressure (BP) comorbidity. We curated 1,304 independent single-nucleotide variants (SNVs) associated with T2D/BP, grouping them into five clusters related to metabolic syndrome, inverse T2D-BP risk, impaired pancreatic beta-cell function, higher adiposity, and vascular dysfunction . Colocalisation with tissue-specific gene expression highlighted significant enrichment in pathways related to thyroid function and fetal development. Partitioned polygenic scores (PGS) derived from these clusters improved risk prediction for T2D-hypertension comorbidity, identifying individuals with more than twice usual susceptibility. These results reveal complex genetic basis of shared T2D and BP mechanistic heterogeneity, enhancing comorbidity risk prediction. Partitioned PGSs offer promising approach for early risk stratification, personalised prevention, and improved management of these interconnected conditions, supporting precision medicine and public health initiatives.
- Open Access
Genetics of Recurrent Miscarriage and Pregnancy Loss in Women’s Reproductive Health
Adverse pregnancy outcomes, such as sporadic and recurrent miscarriages and stillbirths, are significant medical concerns, impacting up to 15% of clinically recognised pregnancies. These outcomes are highly complex and multifactorial, with up to 50% of cases classified as idiopathic, highlighting a substantial gap in our understanding of their biological basis. Along with external risk factors, polygenic variability contributes to idiopathic pregnancy loss, suggesting that large-scale genetic studies could offer insights into its mechanisms, reveal novel drug targets, and lead to new treatments. This study assesses current knowledge from genome-wide association studies (GWAS) using genotyping arrays, whole-genome imputation, and sequencing for variant discovery, emphasising genetic predisposition to adverse pregnancy outcomes. We summarise existing efforts identifying 30 genetic loci associated with pregnancy loss and related endophenotypes, integrating them into a polygenic score (PGS) and conducting a phenome-wide PGS association analysis of 280 ICD-10 outcomes in nearly 500,000 UK Biobank participants. We report associations between pregnancy loss PGS and an increased risk for diaphragmatic hernia (OR[95%CI]=1.02[1.01–1.03], P=9.15×10⁻⁷), eosinophilic esophagitis (OR[95%CI]=1.05[1.03–1.06], P=1.44×10⁻⁶), and asthma with exacerbation (OR[95%CI]=1.02[1.01–1.03], P=1.71×10⁻⁵), significant after correction for multiple testing and suggesting new mechanistic pathophysiology in pregnancy loss susceptibility. Additionally, Mendelian Randomisation (MR) studies identified higher BMI and smoking as risk factors for pregnancy loss, while the roles of caffeine and alcohol intake, maternal age, and family history of miscarriage warrant further investigation through adequately powered MR analyses. Well-designed and comprehensive GWAS studies, particularly across diverse ancestry groups, are urgently needed for idiopathic recurrent pregnancy loss. Such studies should overcome issues with identification of women suffering for this condition and related pregnancy losses to support better care and timely interventions, aiming for healthy live birth outcomes.
Open AccessGenetics of Recurrent Miscarriage and Pregnancy Loss in Women’s Reproductive Health
Adverse pregnancy outcomes, such as sporadic and recurrent miscarriages and stillbirths, are significant medical concerns, impacting up to 15% of clinically recognised pregnancies. These outcomes are highly complex and multifactorial, with up to 50% of cases classified as idiopathic, highlighting a substantial gap in our understanding of their biological basis. Along with external risk factors, polygenic variability contributes to idiopathic pregnancy loss, suggesting that large-scale genetic studies could offer insights into its mechanisms, reveal novel drug targets, and lead to new treatments. This study assesses current knowledge from genome-wide association studies (GWAS) using genotyping arrays, whole-genome imputation, and sequencing for variant discovery, emphasising genetic predisposition to adverse pregnancy outcomes. We summarise existing efforts identifying 30 genetic loci associated with pregnancy loss and related endophenotypes, integrating them into a polygenic score (PGS) and conducting a phenome-wide PGS association analysis of 280 ICD-10 outcomes in nearly 500,000 UK Biobank participants. We report associations between pregnancy loss PGS and an increased risk for diaphragmatic hernia (OR[95%CI]=1.02[1.01–1.03], P=9.15×10⁻⁷), eosinophilic esophagitis (OR[95%CI]=1.05[1.03–1.06], P=1.44×10⁻⁶), and asthma with exacerbation (OR[95%CI]=1.02[1.01–1.03], P=1.71×10⁻⁵), significant after correction for multiple testing and suggesting new mechanistic pathophysiology in pregnancy loss susceptibility. Additionally, Mendelian Randomisation (MR) studies identified higher BMI and smoking as risk factors for pregnancy loss, while the roles of caffeine and alcohol intake, maternal age, and family history of miscarriage warrant further investigation through adequately powered MR analyses. Well-designed and comprehensive GWAS studies, particularly across diverse ancestry groups, are urgently needed for idiopathic recurrent pregnancy loss. Such studies should overcome issues with identification of women suffering for this condition and related pregnancy losses to support better care and timely interventions, aiming for healthy live birth outcomes.
- 30 April 2024
- Published by The R Foundation
comorbidPGS: Assessing Predisposition Between Phenotypes using Polygenic Scores
- 30 April 2024
- Published by The R Foundation
comorbidPGS: Assessing Predisposition Between Phenotypes using Polygenic Scores
- Open Access
- 10 May 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (8) , 962-966
Abdominal obesity is a more important causal risk factor for pancreatic cancer than overall obesity
Obesity and type 2 diabetes (T2D) are associated with increased risk of pancreatic cancer. Here we assessed the relationship between pancreatic cancer and two distinct measures of obesity, namely total adiposity, using BMI, versus abdominal adiposity, using BMI adjusted waist-to-hip ratio (WHRadjBMI) by utilising polygenic scores (PGS) and Mendelian randomisation (MR) analyses. We constructed z-score weighted PGS for BMI and WHRadjBMI using publicly available data and tested for their association with pancreatic cancer defined in UK biobank (UKBB). Using publicly available summary statistics, we then performed bi-directional MR analyses between the two obesity traits and pancreatic cancer. PGSBMI was significantly (multiple testing-corrected) associated with pancreatic cancer (OR[95%CI] = 1.0804[1.025–1.14], P = 0.0037). The significance of association declined after T2D adjustment (OR[95%CI] = 1.073[1.018–1.13], P = 0.00904). PGSWHRadjBMI association with pancreatic cancer was at the margin of statistical significance (OR[95%CI] = 1.047[0.99–1.104], P = 0.086). T2D adjustment effectively lost any suggestive association of PGSWHRadjBMI with pancreatic cancer (OR[95%CI] = 1.039[0.99–1.097], P = 0.14). MR analyses showed a nominally significant causal effect of WHRadjBMI on pancreatic cancer (OR[95%CI] = 1.00095[1.00011–1.0018], P = 0.027) but not for BMI on pancreatic cancer. Overall, we show that abdominal adiposity measured using WHRadjBMI, may be a more important causal risk factor for pancreatic cancer compared to total adiposity, with T2D being a potential driver of this relationship.
- 10 May 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (8) , 962-966
Open AccessAbdominal obesity is a more important causal risk factor for pancreatic cancer than overall obesity
Obesity and type 2 diabetes (T2D) are associated with increased risk of pancreatic cancer. Here we assessed the relationship between pancreatic cancer and two distinct measures of obesity, namely total adiposity, using BMI, versus abdominal adiposity, using BMI adjusted waist-to-hip ratio (WHRadjBMI) by utilising polygenic scores (PGS) and Mendelian randomisation (MR) analyses. We constructed z-score weighted PGS for BMI and WHRadjBMI using publicly available data and tested for their association with pancreatic cancer defined in UK biobank (UKBB). Using publicly available summary statistics, we then performed bi-directional MR analyses between the two obesity traits and pancreatic cancer. PGSBMI was significantly (multiple testing-corrected) associated with pancreatic cancer (OR[95%CI] = 1.0804[1.025–1.14], P = 0.0037). The significance of association declined after T2D adjustment (OR[95%CI] = 1.073[1.018–1.13], P = 0.00904). PGSWHRadjBMI association with pancreatic cancer was at the margin of statistical significance (OR[95%CI] = 1.047[0.99–1.104], P = 0.086). T2D adjustment effectively lost any suggestive association of PGSWHRadjBMI with pancreatic cancer (OR[95%CI] = 1.039[0.99–1.097], P = 0.14). MR analyses showed a nominally significant causal effect of WHRadjBMI on pancreatic cancer (OR[95%CI] = 1.00095[1.00011–1.0018], P = 0.027) but not for BMI on pancreatic cancer. Overall, we show that abdominal adiposity measured using WHRadjBMI, may be a more important causal risk factor for pancreatic cancer compared to total adiposity, with T2D being a potential driver of this relationship.